Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.IDM initiates enrollment in osteosarcoma study
The compassionate access study is being conducted initially at M D Anderson and Memorial-Sloan Kettering Cancer Center in New York. Eligible patients will have a confirmed diagnosis of
The compassionate access study is being conducted initially at M D Anderson and Memorial-Sloan Kettering Cancer Center in New York. Eligible patients will have a confirmed diagnosis of
Medisoft has recently begun marketing and selling the Hypair exhaled Nitric Oxide (NO) analyser in Germany. Aerocrine claims the Medisoft Hypair Analyser infringes four of Aerocrine’s European patents.
The Growth Direct System is claimed to be the first and only automated system for rapid microbial detection that addresses all of the manufacturers’s key testing applications and
Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales. Howard Pien, president and CEO of Medarex, said: “We
Mr Guindon intends to keep assisting the company on a consultancy basis. Biophage is presently considering different options for his replacement on an interim basis. Rosemonde Mandeville, president
The two new products will be marketed under the Extendryl brand name and will be launched in March 2008. Extendryl PEM tablets combine two compounds; a decongestant with
The vials were manufactured by Baxter and then placed by American Health Packaging (AHP) into individually labeled bags for use in pharmacy automation equipment. The AHP packages were
Scott Seaman, chairman of the Opexa’s nominations committee, said: “All of the directors would like to thank David for his valuable contributions to the company and for his
The study (Eortc 40983 Intergroup study) is also referred to as the EPOC trial. Among the 342 eligible patients treated in the EPOC study, perioperative 5-fluorouracil/leucovorin (FOLFOX4 chemotherapy)
It has been predicted that automotive semiconductor revenue will grow by an annual compound rate of 7.7% between 2007 and 2012 as new and potential applications for the